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Abstract
Background: The poly Q polymorphism in AIB1 (amplified in breast cancer) gene is usually
assessed by fragment length analysis which does not reveal the actual sequence variation. The
purpose of this study is to investigate the sequence variation of poly Q encoding region in breast
cancer cell lines at single molecule level, and to determine if the sequence variation is related to
AIB1 gene amplification.
Methods: The polymorphic poly Q encoding region of AIB1 gene was investigated at the single
molecule level by PCR cloning/sequencing. The amplification of AIB1 gene in various breast cancer
cell lines were studied by real-time quantitative PCR.
Results: Significant amplifications (5–23 folds) of AIB1 gene were found in 2 out of 9 (22%) ER
positive cell lines (in BT-474 and MCF-7 but not in BT-20, ZR-75-1, T47D, BT483, MDA-MB-361,
MDA-MB-468 and MDA-MB-330). The AIB1 gene was not amplified in any of the ER negative cell
lines. Different passages of MCF-7 cell lines and their derivatives maintained the feature of AIB1
amplification. When the cells were selected for hormone independence (LCC1) and resistance to
4-hydroxy tamoxifen (4-OH TAM) (LCC2 and R27), ICI 182,780 (LCC9) or 4-OH TAM, KEO and
LY 117018 (LY-2), AIB1 copy number decreased but still remained highly amplified. Sequencing
analysis of poly Q encoding region of AIB1 gene did not reveal specific patterns that could be
correlated with AIB1 gene amplification. However, about 72% of the breast cancer cell lines had at
least one under represented (<20%) extra poly Q encoding sequence patterns that were derived
from the original allele, presumably due to somatic instability. Although all MCF-7 cells and their
variants had the same predominant poly Q encoding sequence pattern of
(CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA of the original cell line, a number of
altered poly Q encoding sequences were found in the derivatives of MCF-7 cell lines.
Conclusion: These data suggest that poly Q encoding region of AIB1 gene is somatic unstable in
breast cancer cell lines. The instability and the sequence characteristics, however, do not appear
to be associated with the level of the gene amplification.
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Background
While predisposition to breast cancer is largely due to
mutations in high penetrance tumor suppressor genes
such as BRCA1 and BRCA2, progression of cancer is the
result of accumulation of genetic alterations. These altera-
tions include gene amplifications, microsatellite instabili-
ties, loss of heterozygosity, and mutations in genes that
play important roles in signal transduction or transcrip-
tion activation pathways leading to tumorigenesis. Gene
amplification in breast cancer was found in several chro-
mosomal locations [1-4]. Among them, ErbB2 (or HER-2/
neu) amplification strongly correlates with steroid recep-
tor negative tumors [5,6], and amplification of
AIB1(amplified in breast cancer 1) gene is prevalent in
estrogen receptor (ER) positive tumors [7,8]. The AIB1
gene is a member of the SRC-1 (steroid receptor coactiva-
tor) family and is also known as RAC3, TRAM-1 or ACTR
[7,9,10]. It is located at chromosome 20q12 region and
encodes a protein of 1420 amino acids containing bHLH-
PAS dimerization domain, a hormone receptor interac-
tion domain, a CBP interaction domain, and histone
acetyltransferase domain [11]. The amplifications and
overexpression of AIB1 gene were found to be a common
phenomenon in breast cancer cell lines and primary
breast cancer tissues [12-15]. Since AIB1 bridges between
nuclear receptors and other coactivators or the transcrip-
tional machinery, its amplification and overexpression
may play crucial roles in the development of breast cancer
and may potentially have influence on the hormonal pre-
vention and treatment for breast cancer.
Toward the C-terminus of AIB1, there is a stretch of poly-
glutamine residues that are encoded by polymorphic CAG
repeats. The expansion of CAG repeats in poly Q contain-
ing proteins underlies a number of neurodegenerative dis-
eases [16,17]. Large expansion of triplet repeats in AIB1
gene does not occur, presumably due to the frequent
interruption by CAA [18]. However somatic instability by
nucleotide substitution such as small insertion or deletion
does occur [18]. In androgen receptor (AR), the length of
the CAG repeats inversely correlates with its transcrip-
tional activity [19,20]. Meanwhile a shorter CAG repeat in
AR is associated with a higher risk of an aggressive prostate
cancer phenotype characterized by extraprostatic exten-
sion, distant metastases, or poor histological grade [21].
In the case of AIB1, it is not clear if the polymorphic
length of poly Q affects the transactivation activity of
AIB1. AIB1 interacts with ER in a ligand-dependent man-
ner [7]. It also interacts with non-steroid nuclear receptors
and transcription co-integrators such as thyroid and retin-
oid receptors and CBP-dependent transcription com-
plexes [22,23]. Thus, amplification of AIB1 gene impacts
on both estrogen dependent and estrogen independent
mechanisms leading to tumorigenesis [24-26]. Although
antiestrogens are the most common type of endocrine
therapy in breast cancer treatment, acquired resistance can
be a major problem in clinical management of initially
responsive breast cancer patients.
Understanding of the quantitative and qualitative changes
of AIB1 gene in estrogen-independent and antiestrogen
resistant breast cancer cell lines may help in the selection
of steroid or non-steroid antiestrogen therapies. Evalua-
tion of AIB1 gene amplification in previous reports is per-
formed by FISH or Southern blot analysis [2,4,7]. In this
report, we use the real-time quantitative PCR (Q-PCR)
technique to assess the amplification of AIB1 gene in var-
ious breast cancer cell lines and primary breast tumors.
We also analyze the sequence characteristics and instabil-
ity of the polymorphic poly Q encoding region at the sin-
gle molecule level by cloning and sequencing of the DNA
region containing CAG repeats.
Methods
Samples and DNA preparation
Primary breast tumor specimens with matching normal
breast tissue samples were obtained from Fu Jen Catholic
University, and Cardinal Tien Hospital, Taiwan, after sur-
gical removal of the tumor according to the IRB approved
protocol. The ER positive breast cancer cell lines were
obtained from Georgetown University Lombardi Com-
prehensive Cancer Center Tissue Culture shared resource
and American Type Cell Culture. A total of 25 cancer and
4 non-cancer breast tissue cell lines were studied. MCF-7
variants include different passages, MCF-7 p19, MCF-7
p72 and MCF-7 derivatives: LCC1 (selected for growth in
vitro without estrogens) [27], LCC2 (selected from LCC1
by treatment with non-steroid antiestrogen 4-OH TAM)
[28], LCC9 (selected from LCC1 by treatment with steroid
antiestrogen ICI 182,780) [29], LY-2 (resistant to 4-OH
TAM, KEO and LY 117018) and R27 (resistant to 4-OH
TAM). AK-47 is derived from parental ER positive cell line
ZR-75-1 with the loss of expression of ER. LCC6 is a more
aggressive form of MDA-MB-435 [30]. A1N4 is a normal
breast cell line that is ER negative. DNA from tissues,
blood and cell cultures was extracted by salting out
method [31].
Preparation of standard DNA for quantitative PCR
A region of 439 bp from exon 5 of AIB1 gene was ampli-
fied with the forward primer; 5'-CAAGCGATCAAATGAG-
GGTAG-3' and the reverse primer; 5'-
CATTGTTTCATATCTCTGGCG-3'. A fragment of 85 bp
from 3' untranslated region of β2-microglobulin gene (β2-
M) was amplified with the forward primer; 5'-TGCT-
GTCTCCATGTTTGATGTATCT-3' and the reverse primer;
5'-TCTCTGCTCCCCACCTCTAAGT-3' [32-34]. These PCR
products were cloned into the pCR 2.1-TOPO vector (Inv-
itrogen). The plasmid DNA was isolated and quantified
using the DU640 Spectrophotometer (Beckman, Fuller-BMC Cancer 2006, 6:111 http://www.biomedcentral.com/1471-2407/6/111
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ton, CA, USA). The copy numbers were calculated from
absorbance at 260 nm and based on the molecular weight
of the resulting plasmid. The plasmid DNAs were serially
diluted over four logs to establish the standard curve giv-
ing a range from 400,000 to 40 copies/µl. In additional set
of experiments the standard curve was constructed using
genomic DNA prepared as a pool of equal amounts of
blood DNA from 7 control individuals with normal AIB1
copy number. 'Normal' genomic DNA (100 ng/µl) was
diluted in water over four logs. Since 1 ng of genomic
DNA contains approximately 330 copies of a single copy
gene, five standards used range from 33000 to 3.3 copies/
µl.
Real-time quantitative PCR (RT Q-PCR)
In real-time Q-PCR analysis, the primers used were 5'-
GAGTTTCCTGGACAAATGAG-3' (forward) and 5'-CATT-
GTTTCATATCTCTGGCG-3' (reverse) for AIB1 gene (Exon
5), and the same primers as used for standard DNA prep-
aration for β2-M gene, yielding 134 bp and 85 bp PCR
products, respectively. The TaqMan probes were FAM-5'
GCCGTATGTTGATGAAAACACCACA 3'-TAMRA and VIC-
5' TTGCTCCACAGGTAGCTCTAGGAGG 3'-TAMRA, for
AIB1 and β2-M gene respectively, each labeled with FAM
or VIC (reporter dye) at the 5' end and TAMRA (quencher
dye) at the 3' end. Each 10 µl real time Q-PCR reaction
mixture contained 1 × TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA), 10 ng of genomic
DNA, 0.3 µM of each primer, and 0.1 µM probe. The actin
gene was also used as a reference. However, since the actin
gene has multiple homologous copies, the data presented
here were referenced to β2-M gene. The amplification was
carried out according to the conditions suggested by the
manufacturer (initial denaturation at 95°C for 10 min
and 40 cycles of 95°C for 15 s and 60°C for 1 min) using
an ABI Prism 7700 Sequence Detection System (Applied
Biosystems, Foster City, CA). Each measurement was per-
formed in triplicate and the threshold cycle numbers (CT)
were measured. The copy number was generated from the
CT  value and standard curve according to previously
described procedures [32-34].
Cloning and sequencing
The poly Q containing fragment was amplified by the for-
ward primer F: 5' GTCTTATACCTGGTGTATTG 3' and the
reverse primer R: 5' CTGGGGGAAGCAGTCACATTAG 3',
yielding a PCR product of 314 bp. The high fidelity ampli-
fication was carried out in a 30 µl reaction mixture con-
taining 10 ng of genomic DNA, 0.2 µM of each primer, 1
× HF 2 PCR buffer, dNTPs, and Advantage-HF 2 polymer-
ase according to the manufacturer's recommendation
(Clontech Laboratories, Palo Alto, CA). After 1 min of ini-
tial denaturation at 94°C, the DNA was amplified by 30
cycles of 45 s at 95°C, 45 s at 55°C and 45 s at 72°C, fol-
lowed by a final extension at 72°C for 5 min. The PCR
products were purified and cloned into pCR2.1-TOPO
(Invitrogen) vector according to the manufacturer's proto-
col. At least 8 clones from each sample were picked for
sequencing using BigDye sequencing kit and analyzed on
an ABI 377 DNA Sequencer (Applied Biosystems, Foster
City, CA). Two primers, F and F2 (5' AGCAGGGTTTTCT-
TAATGCTC 3') were used for sequencing and loading of
reactions onto alternate lanes for easy tracking. The
sequence results were analyzed using sequence analysis
software version 3.4.
Results
Amplification of AIB1 gene
Real-time Q-PCR analysis allows the measurement of
actual copy number of AIB1 gene using a single copy β2-
microglobulin gene as a reference. From the threshold cycle
number and the standard curve, the ratio of the copy
number of AIB1 gene to that of β2-M gene can be calcu-
lated. This ratio can be used as a measure of the amplifica-
tion of the AIB1 gene. The average copy number ratio of
the AIB1/β2-M in the blood samples from 48 age matched
control individuals is determined to be 1.16 ± 0.38. An
AIB1/β2-M ratio above 2 SD of the mean (1.16 + 2 × 0.38
= 1.92) is defined as truly amplified. In addition, all meas-
urements were repeated using a pool of normal genomic
DNAs for standard curve construction. The results
obtained using both methods were practically identical.
We first evaluate the amplification of AIB1 gene in 26 pri-
mary breast tumors (13 ER positive and 13 ER negative)
and corresponding surrounding normal breast tissue sam-
ples. AIB1 gene was found to be amplified in 1 ER positive
tumor sample that constitutes 3.8% of total or 7.6% of ER
positive tumors. This result is consistent with previous
report [3,7,13].
As shown in Table 1, 9 out of 29 cell lines had elevated
AIB1 at 2SD above the mean. All of them were ER positive.
AIB1 gene was not amplified in 7 ER positive cell lines:
BT20, ZR-75-1, T47D, BT483, MDA-MB-361, MDA-MB-
468 and MDA-MB-330. None of the 13 ER negative cell
lines showed significant AIB1  amplification. Some cell
lines are derivatives of others. For example, AK-47 is
derived from ER positive ZR-75-1 cell line. In AK-47 cells,
loss of ER expression did not have any effect on AIB1 copy
number. The amplification of AIB1 gene in different pas-
sages of ER positive MCF-7 cell lines remains at high levels
of 18–23 fold of control. Loss of estrogen dependence in
LCC1 is accompanied by moderate decrease in AIB1 gene
amplification (13.5 fold in LCC1 versus 22.2 fold in MCF-
7). The level of AIB1 gene amplification was reduced to
14.6 fold when the estrogen-independent cells became
resistant to antiestrogen 4-OH TAM treatment (LCC2).
Similar decrease in amplification (15.6 fold of control) of
AIB1 gene was observed in estrogen-independent cell lineBMC Cancer 2006, 6:111 http://www.biomedcentral.com/1471-2407/6/111
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that has gained antiestrogen resistance to both non-ster-
oid, 4-OH TAM, and steroid, ICI 182,780 antiestrogens
(LCC9) (Table 1).
Somatic instability of poly Q encoding region of AIB1 gene 
in breast cancer cell lines
The polymorphic poly Q encoding region of AIB1 con-
tains CAG repeat that is frequently interrupted by CAA's.
The poly Q region is part of the histone acetyltransferase
domain. It is also where the recruitment and interactions
with other components of the transcription activator com-
plex takes place. In order to investigate if qualitative alter-
ation in this region accompanied the quantitative change
of AIB1 gene in breast cancer cell lines, we cloned and
sequenced the poly Q encoding region of the gene. The
cloning/sequencing technique resolved the heterogene-
ous poly Q encoding sequences into distinct sequences,
thus allowing the analysis at the single molecule level. At
least 8 clones from each cell line were selected and
sequenced. Theoretically, there should be only 2 distinct
sequence patterns if the cell line is heterozygous for AIB1
allele and one distinct sequence pattern if it is
homozygous. However, 18/25 (72%) (data partially
shown in Table 2) of the cell lines contain at least one
poly Q encoding sequence pattern that represents less
than 20% of the sequenced clones of the cell line. These
results suggest that the under-represented sequences prob-
ably arise from the parental sequence by somatic muta-
tion. Indeed these rare sequences differ from their
parental sequence by one base pair substitution (CAG to
CAA) or by insertion or deletion of CAGs. The high degree
(72% of the cell lines) of somatic instability is probably
characteristic for cancer cell lines since it only occurs in
less than 5% (2/43) of the normal controls. We analyzed
normal A1N4 cell line at two different times. The first
time, ten clones of A1N4 cell line were sequenced. Pattern
2 (Table 2), (CAG)6CAA(CAG)9(CAACAG)3(CAACAG-
CAG)2CAA, was found in 4 clones, and pattern 17,
(CAG)4CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA was
found in 6 clones. The second time, 31 clones were
sequenced. Sixteen had pattern 2 and 15 had pattern 17.
There was no occurrence of "extra" poly Q encoding
sequence. These results suggest that the occurrence of rare
sequences is not due to cloning/PCR artifact.
Association between poly Q length or its specific encoding
sequence with AIB1  amplification was not recognized
(Table 2). Somatic instability occurred in all variants of
MCF-7 cell line, although they all maintain the parental
allele as the predominant coding sequences (pattern 1).
Two new sequences arise by insertion of 2 and 3 CAGs in
passage 19. Another two new sequences occur in passage
72 by deletion of 1 and 2 CAG repeats. Similar somatic
mutations occur in cell lines LCC1, LCC2, LCC9, LY-2 and
R27. These mutations seem to occur randomly and inde-
pendently in each cell line. There is not any single
sequence that occurs more frequently than others, except
pattern 5, which occurs 3 times by losing 1 CAG directly
from the parental sequence.
AK47 was derived from ZR-75-1 by losing its ER activity.
During the establishment of the cell line, additional
somatic mutations occurred in the polyglutamine region
(patterns 11 and 16). The poly Q encoding sequence of
AIB1 gene seems to be quite unstable in MDA-MB435 cell
line. It has 4 distinct poly Q encoding sequence patterns
with pattern 9 as the predominant one. Its variant LCC6
had a total of 7 different sequence patterns. These data are
consistent with the genomic instability that is characteris-
tic for cancer cells. Although poly Q encoding sequence
Table 1: The ER status, AIB1 amplification, and poly Q encoding 
sequences in breast cell lines






MCF-10A - 1.1 3
MCF-10A neo - 1.3 3
A1N4b -2 . 0 2
AK-47 -1 . 4 3
MDA-MB435 -1 . 3 4
LCC6 -2 . 0 7
MDA-MB157 - 1.1 6
MDA-MB134V - 1.4 2
MDA-MB231N - 1.2 2
HBL100 - 1.2 1
ZR-75-30 - 1.7 1
HS 578T - 1.9 2
HS 578BST - 1.1 2
MCF7 +2 2 . 2 1
MCF-7 P19 +1 8 . 7 3
MCF-7 P72 +2 2 . 8 3
LY-2 +1 9 . 9 2
R27 +1 9 . 4 2
LCC1 +1 3 . 5 3
LCC2 +1 4 . 6 2
LCC9 +1 5 . 6 2
BT474 + 4.9 2
BT-483 + 1.9 4
BT20 + 1.7 2
MDA-MB468 + 1.7 2
ZR-75-1 +1 . 5 2
MDA-MB361 + 1.3 2
T47D + 1.0 5
MDA-MB330 + 0.9 2
aLCC1: estrogen independent and responsive which is selected for 
growth in vivo without estrogens; LCC2: selected from LCC1 by 
treatment with 4-OH TAM; LCC9: selected from LCC1 by treatment 
with ICI 182780, resistant to ICI182780 and 4-OH TAM:, LY-2: 
selected for resistance to 4-OH TAM, KEO and LY 117018; R27: able 
to grow in the presence of 4-OH TAM. LCC6 is the more aggressive 
variant of MD-MB435. AK-47 is the variant derived from ZR-75-1. 
A1N4 is a normal breast cell line.
bCell lines listed in Table 2 are in bold.BMC Cancer 2006, 6:111 http://www.biomedcentral.com/1471-2407/6/111
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patterns do not seem to directly link to AIB1 gene amplifi-
cation, it is possible that the alteration in poly Q length
affects protein-protein interaction, thus, the transactiva-
tion activity of AIB1. While most alterations do not change
poly Q length significantly, rare sequence pattern in LCC2
with much shorter (only 14 repeats) poly glutamine tract
may affect the co-transactivating activity of AIB1  gene.
Discussion
Genetic and clinical phenotypic heterogeneity is the
prominent characteristic of breast cancer. Multiple genetic
alterations contribute to breast cancer development and
progression [35,36]. The occurrence of DNA amplifica-
tions in breast cancer had been studied by Southern blot
[1], FISH (fluorescence in situ hybridization) [4] and
CGH methods (comparative genomic hybridization) [37-
39]. We developed real time quantitative PCR method to
more accurately assess the amplification of AIB1 gene in
breast cancer cell lines. Amplification of AIB1 in breast
cancer cell lines; BT-474 and MCF-7 were first reported by
Guan et al. [3]. By FISH analysis, Anzick et al. [7] observed
>20 fold amplification of AIB1 gene in three ER positive
breast cancer cell lines (BT-474, MCF-7 and ZR-75-1) and,
to a lesser extent, in 10% primary breast tumors. In this
study we did not detect significant amplification in ZR-75-
1 cell line. The discrepancy may be explained by a differ-
ent source of the cell line or by spontaneous change of the
cell line during passages. In addition, FISH analysis is
Table 2: Poly Q sequence patterns and AIB1 amplification level in MCF7 and its variants
Cell linea amplification Sequence patterns Pattern (Q)n Frequency
MCF-7 22.3 (CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 12 6 7 / 7
MCF-7 P19 18.7 (CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 12 6 7 / 9
(CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 2 29 1/9
(CAG)5CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 3 28 1/9
MCF-7 P72 22.8 (CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 12 6 5 / 7
(CAG)3CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 4 25 1/7
(CAG)3CAA(CAG)7(CAACAG)3(CAACAGCAG)2CAA 5 24 1/7
LCC1 13.5 (CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 12 6 7 / 9
(CAG)3CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 4 25 1/9
(CAG)3CAA(CAG)14(CAACAG)2(CAACAGCAG)2CAA 6 29 1/9
LCC2 14.6 (CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 12 6 4 / 5
CAG(CAACAG)3(CAACAGCAG)2CAA 7 14 1/5
LCC9 15.6 (CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 12 6 7 / 8
(CAG)3CAA(CAG)2CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 8 29 1/8
LY-2 19.9 (CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 12 69 / 1 0
(CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 9 28 1/10
R27 19.4 (CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 12 6 8 / 9
(CAG)3CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 4 25 1/9
MDA-MB435 1.3 (CAG)3CAA(CAG)2CAA(CAG)11(CAACAG)2(CAACAGCAG)2CAA 10 29 2/8
(CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 9 28 3/8
(CAG)3CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 1 26 2/8
(CAG)6CAA(CAG)8(CAACAG)2(CAACAGCAG)2CAA 11 26 1/8
LCC6 2.0 (CAG)3CAA(CAG)2CAA(CAG)10(CAACAG)2(CAACAGCAG)2CAA 12 28 1/9
(CAG)3CAA(CAG)2CAA(CAG)6(CAACAG)3(CAACAGCAG)2CAA 13 26 1/9
(CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 9 28 3/9
(CAG)3CAA(CAG)2CAA(CAG)10(CAACAG)3(CAACAGCAG)2CAA 14 30 1/9
(CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 15 28 1/9
(CAG)3CAA(CAG)2CAA(CAG)11(CAACAG)2(CAACAGCAG)2CAA 10 29 1/9
(CAG)3CAA(CAG)2CAACAGCAA(CAG)8(CAACAG)2(CAACAGCAG)2CAA 16 28 1/9
ZR-75-1 1.5 (CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 2 29 6/7
(CAG)5CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 3 28 1/7
AK-47 1.4 (CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 2 29 2/8
(CAG)6CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 11 28 5/8
(CAG)5CAA(CAG)8(CAACAG)3(CAACAGCAG)2CAA 15 27 1/8
A1N4 2.0 (CAG)6CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 2 29 20/41
(CAG)4CAA(CAG)9(CAACAG)3(CAACAGCAG)2CAA 17 27 21/41
aLCC1: estrogen independent and responsive which is selected for growth in vivo without estrogens; LCC2: selected from LCC1 by treatment with 
4-OH TAM; LCC9: selected from LCC1 by treatment with ICI 182780, resistant to ICI182780 and 4-OH TAM:, LY-2: selected for resistance to 4-
OH TAM, KEO and LY 117018; R27: able to grow in the presence of 4-OH TAM. LCC6 is the more aggressive variant of MD-MB435. AK-47 is the 
variant derived from ZR-75-1. A1N4 is a normal breast cell line. The parental sequence patterns are in bold.BMC Cancer 2006, 6:111 http://www.biomedcentral.com/1471-2407/6/111
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restricted to a few cells, whereas real time qPCR analysis
measures the gene in the overall DNA extract. Glaeser et
al. [2] used the quantitative differential PCR to determine
the amplification level of AIB1 and found no amplifica-
tion in breast or endometrial carcinomas. These methods
did not give actual copy numbers of the gene. In this
study, we used real-time Q-PCR to determine the level of
AIB1  amplification. The ability of real-time Q-PCR to
detect the fluorescent signal from degraded sequence spe-
cific TaqMan probe at the very beginning period of expo-
nential stage offered an accurate way of DNA
quantification. When compared to CGH, FISH and South-
ern blot analysis, this method has the advantage of high
sensitivity, reproducibility, and efficiency.
If only the original cell lines were counted, the AIB1 gene
was amplified in 2 out of 9 ER positive and none of 10 ER
negative cell lines. Higher degree (22%) of AIB1 amplifi-
cation in ER positive breast cancer cell lines may suggest
the association between AIB1gene amplification and ER
status. This is further supported by the observation that
the AIB1 amplification moderately decreased when cells
became ER independent as LCC1, LCC2 and LCC9 con-
sistent with the role of AIB1 in ER-dependent signaling.
All MCF-7 variant cell lines maintain high level of AIB1
gene amplification of the parental cells. Additional gain of
resistance to an antiestrogen, ICI182,780, does not have
significant effect on AIB1 amplification (from LCC1 to
LCC9). Similarly, resistance to 4-OH TAM is not consist-
ently accompanied with the change in AIB1 gene amplifi-
cation. LY-2, R27, and LCC2 were all selected from
estrogen dependent MCF-7 cells against high dose of 4-
OH TAM. AIB1 gene amplification in LY-2 and R27 cell
lines remained almost unchanged, whereas in LCC2, AIB1
gene amplification is moderately decreased. These data
suggest that resistance to 4-OH TAM does not necessarily
affect AIB1 gene amplification. It should be noted that in
LCC2 there is a short poly Q containing mutant AIB1 and
lower expression of the gene may be compensated by the
increase in co-transactivation activity of the mutant pro-
tein. Our observation of variations in AIB1 gene amplifi-
cation in various derivatives of MCF-7 cell clines is
consistent with the previous report in which several MCF-
7 sublines were shown to have the capacity to generate
clonal heterogeneity. This represents an important selec-
tive advantage in MCF-7 in leading to aggressive and met-
astatic forms of the disease [40].
Besides the quantitative regulation of AIB1 gene in breast
cancer cell lines, the AIB1  gene contains CAG repeat
region which is a target for genetic instability in tumor
progression. Large expansion of triplet repeat occurs in
various neurodegenerative diseases [41-43]. These abnor-
mal proteins form large aggregates that have been shown
to tie up transcription factors that bind poly Q such as
CREB [44]. The poly Q tract in the androgen receptor (AR)
gene is unique in that the large expansion of poly Q
encoding CAG repeat causes the X-linked spinal bulbar
muscular atrophy (SBMA, or Kennedy Disease) [19,20],
but short poly Q of AR is correlated with hormone-
dependent transactivation [19,20] and more aggressive
form of cancer [21,45]. AIB1  shares several structural/
functional similarities with AR. Both genes are involved in
nuclear receptor mediated regulation of gene expression.
Due to frequent interruption with CAA's, large expansion
of the triplet was not observed in AIB1 gene. This region,
however, was quite unstable as evidenced by frequent
CAA/CAG changes and small insertions and deletions.
The PCR/cloning strategy allows us to investigate the pol-
ymorphic poly Q encoding region at single molecule
level. Since we only sequenced a small number of clones
from each individual, we cannot exclude the possibility
that the under-represented alleles may be lost in PCR/
cloning/sequencing process. Several distinct poly Q
encoding sequence patterns were observed in LCC-6,
T47D, and MDA-MB157. T47D is a cell line of notable
genetic instability that was observed in the estrogen recep-
tor gene [46]. LCC6 cell line which formed ascites was a
more aggressive form of MDA-MB435 [30]. Since various
rare poly Q encoding sequences seem to arise randomly
and independently in different cell lines regardless of the
AIB1 gene amplification levels, we attribute these somatic
mutations to genetic mutability in cancer cells.
Conclusion
The poly Q encoding sequence of AIB1 gene is genetically
unstable and is an easy target for somatic mutations in
cancer cells.AIB1  gene amplification occurs in only a
small fraction of ER positive primary breast tumors and
breast cancer cell lines. AIB1 gene amplification has not
been found in ER negative primary tumor or breast cancer
cell lines. Gain of estrogen independence and resistance to
steroid antiestrogen may be accompanied by moderate
decrease of AIB1 gene amplification.
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